Clinical Report: Efficacy of High-Affinity Monoclonal Antibodies Against Resistant Strains of Plague
Overview
This study evaluates the protective efficacy of two monoclonal antibodies, Fm3 and Fm25, against virulent and drug-resistant strains of Yersinia pestis.
Background
Yersinia pestis is a highly infectious agent responsible for plague, which remains a public health concern in various regions worldwide. The emergence of antibiotic-resistant strains has necessitated the exploration of alternative therapeutic strategies, including monoclonal antibodies. This study addresses the efficacy of mAbs against resistant strains of Y. pestis.
Data Highlights
Antibody
Dosage (µg)
Survival Rate
Fm3
100
100%
Fm3
20
25%
Fm3
4
0%
Fm25
100
100%
Fm25
20
0%
Fm25
4
0%
Key Findings
Fm3 and Fm25 provided 100% protection against Y. pestis strain 141 at a dosage of 100 µg.
At a dosage of 20 µg, Fm3 offered partial protection with a survival rate of 25%.
Neither mAb showed protective efficacy at dosages of 20 µg or 4 µg against the drug-resistant strain S19960127.
Fm25 achieved total survival against the drug-resistant strain at 100 µg.
All subjects in the 4 µg treatment cohorts died within approximately 10 days of infection.
Clinical Implications
Current guidelines do not include mAbs as a recommended treatment for plague.
Conclusion
The study demonstrates the protective efficacy of mAbs Fm3 and Fm25 against virulent and drug-resistant Y. pestis.
